Advertisement

Taurine 11 pp 61-70 | Cite as

Taurine Chloramine Inhibits Osteoclastic Differentiation and Osteoclast Marker Expression in RAW 264.7 Cells

  • In Soon Kang
  • Chaekyun KimEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1155)

Abstract

Taurine is an abundant sulfur-containing amino acid in myeloid cells. It undergoes halogenation in activated phagocytes and is converted to taurine chloramine (TauCl) and taurine bromamine. Bone homeostasis is mediated by the balance between bone-forming osteoblasts and bone-resorbing osteoclasts. Osteoclasts are bone-resorbing multinucleated cells differentiated from monocyte/macrophage precursor cells in response to receptor activator of NF-κB ligand (RANKL). In this study, we investigated the effect of TauCl on RANKL-induced osteoclastogenesis from RAW 264.7 macrophages. TauCl inhibited the formation of multi-nucleated osteoclast and the activity of tartrate-resistant acid phosphatase (TRAP). TauCl decreased the mRNA expression of osteoclast markers, such as TRAP, cathepsin K, and calcitonin receptor. TauCl also inhibited expression of the transcription factors, c-Fos and nuclear factor of activated T cells, which are important for osteoclast differentiation. These results suggest that TauCl might be used as a therapeutic agent to treat bone diseases associated with excessive bone resorption.

Keywords

Taurine chloramine Osteoclast Macrophage Receptor activator of NF-κB ligand (RANKL) Tartrate-resistant acid phosphatase (TRAP) Nuclear factor of activated T cells (NFATc) 

Abbreviations

BMMs

Bone marrow-derived monocyte/macrophage precursor cells

CTR

Calcitonin receptor

CTSK

Cathepsin K

M-CSF

Macrophage colony-stimulating factor

NFATc1

Nuclear factor of activated T cell 1

NF-κB

Nuclear factor-κB

RANKL

Receptor activator of nuclear factor-κB ligand

TauCl

Taurine chloramine

TNF

Tumor necrosis factor

TRAF6

TNF receptor-associated factor 6

TRAP

Tartrate-resistant acid phosphatase

Notes

Acknowledgements

This work was supported by the Inha University Research Fund.

References

  1. Barua M, Liu Y, Quinn MR (2001) Taurine chloramine inhibits inducible nitric oxide synthase and TNF-α gene expression in activated alveolar macrophages: decreased NF-κB activation and IκB kinase activity. J Immunol 167:2275–2281CrossRefGoogle Scholar
  2. Boyce BF, Yao Z, Xing L (2009) Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr 19:171–180CrossRefGoogle Scholar
  3. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342CrossRefGoogle Scholar
  4. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G (2004) Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 164:509–514CrossRefGoogle Scholar
  5. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42:200–211CrossRefGoogle Scholar
  6. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443–448CrossRefGoogle Scholar
  7. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, Evans MJ, Cox TM (1996) Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 122:3151–3162PubMedGoogle Scholar
  8. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia X, Elliot R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540–3545CrossRefGoogle Scholar
  9. Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101–163CrossRefGoogle Scholar
  10. Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, Miyamoto Y (2002) Oxidation of IκBα at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-κB activation. J Biol Chem 277:24049–24056CrossRefGoogle Scholar
  11. Kim C, Cha YN (2014) Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids 46:89–100CrossRefGoogle Scholar
  12. Kim C, Dinauer MC (2001) Rac2 is an essential regulator of neutrophil nicotinamide adenine dinucleotide phosphate oxidase activation in response to specific signaling pathways. J Immunol 166:1223–1232CrossRefGoogle Scholar
  13. Kim C, Kang IS (2015) Taurine chloramine, a taurine metabolite from activated neutrophils, inhibits osteoclastogenesis by suppressing NFATc1 expression. Adv Exp Med Biol 803:99–107CrossRefGoogle Scholar
  14. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N (2005a) Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280:35209–35216CrossRefGoogle Scholar
  15. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H (2005b) Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 280:32905–32913CrossRefGoogle Scholar
  16. Kim C, Jang JS, Cho MR, Agarawal SR, Cha YN (2010) Taurine chloramine induces heme oxygenase-1 expression via Nrf2 activation in murine macrophages. Int Immunopharmacol 10:440–446CrossRefGoogle Scholar
  17. Learn DB, Fried VA, Thomas EL (1990) Taurine and hypotaurine content of human leukocytes. J Leukoc Biol 48:174–182CrossRefGoogle Scholar
  18. Marcinkiewicz J, Kontny E (2014) Taurine and inflammatory diseases. Amino Acids 46:7–20CrossRefGoogle Scholar
  19. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y (2004) Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279:45969–45979CrossRefGoogle Scholar
  20. Nakanishi A, Hie M, Iitsuka N, Tsukamoto I (2013) A crucial role for reactive oxygen species in macrophage colony-stimulating factor-induced RANK expression in osteoclastic differentiation. Int J Mol Med 31:874–880CrossRefGoogle Scholar
  21. Naot D, Cornish J (2008) The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 43:813–818CrossRefGoogle Scholar
  22. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 78:355–360CrossRefGoogle Scholar
  23. Piao S, Cha YN, Kim C (2011) Taurine chloramine protects RAW 264.7 macrophages against hydrogen peroxide-induced apoptosis by increasing antioxidants. J Clin Biochem Nutr 49:50–56CrossRefGoogle Scholar
  24. Sun Jang J, Piao S, Cha YN, Kim C (2009) Taurine chloramine activates Nr-2, increases HO-1 expression, and protects cells from death caused by hydrogen peroxide. J Clin Biochem Nutr 45:37–43CrossRefGoogle Scholar
  25. Takahashi N, Udagawa N, Kobayashi Y, Suda T (2007) Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med 135:285–301CrossRefGoogle Scholar
  26. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901CrossRefGoogle Scholar
  27. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508CrossRefGoogle Scholar
  28. Theill LE, Boyle WJ, Penninger JM (2002) RANKL and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795–823CrossRefGoogle Scholar
  29. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner EF (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741–745CrossRefGoogle Scholar
  30. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602CrossRefGoogle Scholar
  31. Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclast. Int J Biochem Cell Biol 42:576–579CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Laboratory of Leukocyte Signaling Research, Department of PharmacologyInha University School of MedicineIncheonSouth Korea

Personalised recommendations